Metabolic · HGH C-terminal fragment (research)
AOD-9604
- Drug class
- HGH C-terminal fragment (research)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What AOD-9604 is studied for
- Fat metabolism and lipolysis (preclinical and small human trials)
- Cartilage repair research
- Body composition support
Mechanism of action
Mimics the lipolytic C-terminus of HGH without binding the growth hormone receptor. Stimulates fat breakdown and inhibits lipogenesis without affecting blood glucose or IGF-1 levels.
Frequently asked questions
Does AOD-9604 cause weight loss?
Human trials (Metabolic Pharmaceuticals, phase 2) showed modest weight loss vs. placebo over 12–24 weeks — meaningfully less than GLP-1 medications.
How is it dosed?
Daily subcutaneous injection (commonly 250–500 mcg/day, often morning, fasted). Cycled in most protocols.
Side effects?
Generally well tolerated in trials. Mild injection-site reactions; no significant impact on glucose, insulin, or IGF-1.
Is it FDA-approved?
No. Original obesity development was discontinued. It is sometimes used in compounded form for body-composition support.
